CN114195894B - 一种靶向4-1bb的抗体及其应用 - Google Patents

一种靶向4-1bb的抗体及其应用 Download PDF

Info

Publication number
CN114195894B
CN114195894B CN202011025265.9A CN202011025265A CN114195894B CN 114195894 B CN114195894 B CN 114195894B CN 202011025265 A CN202011025265 A CN 202011025265A CN 114195894 B CN114195894 B CN 114195894B
Authority
CN
China
Prior art keywords
gly
ser
ala
tyr
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202011025265.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN114195894A (zh
Inventor
翟天航
缪小牛
徐祎凤
王超
曾竣玮
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
BIO-NTE (Zhuhai) Pharmaceutical R&D Co., Ltd.
Original Assignee
Biotheus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotheus Inc filed Critical Biotheus Inc
Priority to JP2023517935A priority Critical patent/JP2023542900A/ja
Priority to EP21868697.0A priority patent/EP4215547A4/en
Priority to KR1020237012083A priority patent/KR20230070238A/ko
Priority to PCT/CN2021/118955 priority patent/WO2022057875A1/zh
Priority to AU2021342525A priority patent/AU2021342525A1/en
Priority to CA3195676A priority patent/CA3195676A1/en
Priority to CN202180062285.XA priority patent/CN116490206A/zh
Priority to US18/245,691 priority patent/US20230357422A1/en
Publication of CN114195894A publication Critical patent/CN114195894A/zh
Application granted granted Critical
Publication of CN114195894B publication Critical patent/CN114195894B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30 CD40 or CD95

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Hospice & Palliative Care (AREA)
CN202011025265.9A 2020-09-17 2020-09-25 一种靶向4-1bb的抗体及其应用 Active CN114195894B (zh)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP21868697.0A EP4215547A4 (en) 2020-09-17 2021-09-17 SINGLE-DOMAIN ANTIBODY TARGETING 4-1BB, ITS FUSION PROTEIN, PHARMACEUTICAL COMPOSITION AND USE THEREOF
KR1020237012083A KR20230070238A (ko) 2020-09-17 2021-09-17 4-1bb를 표적으로 하는 단일 도메인 항체, 이의 융합 단백질, 이의 약제학적 조성물 및 용도
PCT/CN2021/118955 WO2022057875A1 (zh) 2020-09-17 2021-09-17 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途
AU2021342525A AU2021342525A1 (en) 2020-09-17 2021-09-17 Single-domain antibody targeting 4-1bb, fusion protein thereof, pharmaceutical composition and use thereof
JP2023517935A JP2023542900A (ja) 2020-09-17 2021-09-17 ４－１ｂｂを標的とする単一ドメイン抗体、その融合タンパク質、その医薬組成物及び使用
CA3195676A CA3195676A1 (en) 2020-09-17 2021-09-17 Single-domain antibody targeting 4-1bb, fusion protein thereof, pharmaceutical composition and use thereof
CN202180062285.XA CN116490206A (zh) 2020-09-17 2021-09-17 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途
US18/245,691 US20230357422A1 (en) 2020-09-17 2021-09-17 Single-domain antibody targeting 4-1bb, fusion protein thereof, pharmaceutical composition and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020109818355 2020-09-17
CN202010981835 2020-09-17

Publications (2)

Publication Number Publication Date
CN114195894A CN114195894A (zh) 2022-03-18
CN114195894B true CN114195894B (zh) 2025-02-25

Family

ID=80645420

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202011025265.9A Active CN114195894B (zh) 2020-09-17 2020-09-25 一种靶向4-1bb的抗体及其应用
CN202180062285.XA Pending CN116490206A (zh) 2020-09-17 2021-09-17 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202180062285.XA Pending CN116490206A (zh) 2020-09-17 2021-09-17 靶向4-1bb的单域抗体、其融合蛋白、药物组合物及用途

Country Status (8)

Country Link
US (1) US20230357422A1 (https=)
EP (1) EP4215547A4 (https=)
JP (1) JP2023542900A (https=)
KR (1) KR20230070238A (https=)
CN (2) CN114195894B (https=)
AU (1) AU2021342525A1 (https=)
CA (1) CA3195676A1 (https=)
WO (1) WO2022057875A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250075621A (ko) * 2022-09-20 2025-05-28 바이오세우스 인크. 항체 및 종양 저항에서의 이의 용도
KR20250157389A (ko) * 2023-03-01 2025-11-04 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 Fap/4-1bb/cd40 결합 분자 및 이의 의학적 용도
WO2025002405A1 (zh) * 2023-06-30 2025-01-02 百奥泰生物制药股份有限公司 4-1bb结合蛋白
CN117736330B (zh) * 2024-01-24 2024-05-17 上海沙砾生物科技有限公司 肿瘤坏死因子超家族受体9的特异性抗原结合蛋白及其应用
WO2025214249A1 (en) * 2024-04-12 2025-10-16 Suzhou Biomissile Pharmaceuticals Co., Ltd. Anti-4-bb single domain antibodies, bispecific antibodies and uses thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110627906A (zh) * 2019-10-10 2019-12-31 上海洛启生物医药技术有限公司 抗pd-l1/4-1bb双特异性抗体及其用途
CN111065652A (zh) * 2018-01-22 2020-04-24 江苏恒瑞医药股份有限公司 抗4-1bb抗体、其抗原结合片段及其医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US7288638B2 (en) * 2003-10-10 2007-10-30 Bristol-Myers Squibb Company Fully human antibodies against human 4-1BB
PT2614082T (pt) * 2010-09-09 2018-12-03 Pfizer Moléculas de ligação a 4-1bb
KR20180096789A (ko) * 2016-01-11 2018-08-29 인히브릭스, 인크. 다가 및 다중특이적 41bb-결합 융합 단백질
US10174122B2 (en) * 2017-01-06 2019-01-08 Eutilex Co., Ltd. Anti-human 4-1BB antibodies and uses thereof
WO2019092452A1 (en) * 2017-11-13 2019-05-16 Crescendo Biologics Limited Molecules that bind to cd137 and psma
WO2019109238A1 (en) * 2017-12-05 2019-06-13 Lyvgen Biopharma Co., Ltd. Anti-cd137 antibodies and uses thereof
CN109970865B (zh) * 2017-12-28 2022-10-04 上海细胞治疗研究院 一种cd137双向激活共刺激分子受体及其用途
WO2020023553A1 (en) * 2018-07-24 2020-01-30 Inhibrx, Inc. Multispecific polypeptide constructs containing a constrained cd3 binding domain and a receptor binding region and methods of using the same

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111065652A (zh) * 2018-01-22 2020-04-24 江苏恒瑞医药股份有限公司 抗4-1bb抗体、其抗原结合片段及其医药用途
CN110627906A (zh) * 2019-10-10 2019-12-31 上海洛启生物医药技术有限公司 抗pd-l1/4-1bb双特异性抗体及其用途

Also Published As

Publication number Publication date
JP2023542900A (ja) 2023-10-12
CN114195894A (zh) 2022-03-18
CA3195676A1 (en) 2022-03-24
CN116490206A (zh) 2023-07-25
EP4215547A4 (en) 2024-12-04
AU2021342525A9 (en) 2023-07-06
WO2022057875A1 (zh) 2022-03-24
AU2021342525A1 (en) 2023-04-27
KR20230070238A (ko) 2023-05-22
EP4215547A1 (en) 2023-07-26
US20230357422A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
CN114502588B (zh) 一种抗pd-l1单域抗体及其衍生物和用途
CN109096396B (zh) 一种抗pd-l1人源化纳米抗体及其应用
AU2017305366B2 (en) Anti-PD-L1 nanobody and use thereof
CN114195894B (zh) 一种靶向4-1bb的抗体及其应用
US11292841B2 (en) Anti-PD-1 nano-antibody and application thereof
CN107216389B (zh) 抗pd-l1纳米抗体及其编码序列和用途
CN114195900B (zh) 一种抗4-1bb/pd-l1双特异性抗体及其用途
CN110835371A (zh) 抗ccr8单克隆抗体及其应用
CN113461825B (zh) 一种抗pd-l2纳米抗体及其应用
CN111995685B (zh) 一种靶向her2和pd-1的双特异性抗体及其应用
CN118754989B (zh) 一种抗her2纳米抗体及其制备方法和应用
WO2025045097A1 (zh) 靶向hbv全长包膜蛋白的单域抗体及其用途
CN115124621B (zh) 靶向pd-l1的纳米抗体及其制备方法和应用
WO2023116781A1 (zh) 一种新型pd1单域抗体的开发
CN115304680A (zh) 基于Pep42构建的双特异性细胞接合器分子的制备及其应用
CN106957364A (zh) 一种单克隆抗体FnAb12及其应用
US20250136695A1 (en) Development of novel pdl1 single-domain antibody
WO2026085716A1 (zh) 新型il-18替代物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CP03 Change of name, title or address
CP03 Change of name, title or address

Address after: 519085, No. 1, Building 4, Unit 10-B, Keji 7th Road, Tangjia Bay Town, Xiangzhou District, Zhuhai City, Guangdong Province

Patentee after: BIO-NTE (Zhuhai) Pharmaceutical R&D Co., Ltd.

Country or region after: China

Address before: 519080 Guangdong Province, Zhuhai City, Xiangzhou District, Tangjia Bay Town, Keji 7th Road No. 1, Building 4, Unit 10-B

Patentee before: Pumis Biotechnology (Zhuhai) Co.,Ltd.

Country or region before: China